Literature DB >> 20930868

Management of overactive bladder.

Dev M Gulur1, Marcus J Drake.   

Abstract

Many people are affected by urinary urgency, which can be highly bothersome. Urgency is the cornerstone symptom of overactive bladder (OAB), commonly occurring in conjunction with urinary frequency and nocturia. Once other medical causes of similar symptoms have been excluded, first-line OAB management comprises fluid intake advice and bladder training, supplemented by antimuscarinic drugs if necessary. Urodynamic confirmation of the diagnosis is required for OAB patients whose symptoms are refractory to first-line interventions. If patients are severely bothered by OAB despite optimization of medical treatment, they may proceed to invasive treatments, including neuromodulation, enterocystoplasty, detrusor myectomy, or urinary diversion. Our burgeoning understanding of the complex cellular, neural and integrative physiology of the bladder offers new insights into the causative mechanisms of OAB, and reasons why patients sometimes fail to respond to treatment. Study of sensory information pathways in the lower urinary tract has led to identification of the urothelium, afferent nerves and interstitial cells as key cellular elements in OAB. In-depth knowledge of the hierarchy of central nervous system control is lacking, but functional imaging is beginning to elucidate the challenges that lie ahead. New treatments under investigation include botulinum neurotoxin-A injection, oral β(3)-adrenergic agonists, and novel modalities for nerve stimulation. The subjective nature of urinary urgency, the lack of animal models and the multifactorial pathophysiology of OAB present significant challenges to effective clinical management.

Entities:  

Mesh:

Year:  2010        PMID: 20930868     DOI: 10.1038/nrurol.2010.147

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  109 in total

Review 1.  Ambulatory urodynamics.

Authors:  S E Bristow; D E Neal
Journal:  Br J Urol       Date:  1996-03

Review 2.  Bladder activation: afferent mechanisms.

Authors:  Karl-Erik Andersson
Journal:  Urology       Date:  2002-05       Impact factor: 2.649

Review 3.  New frontiers in intravesical therapies and drug delivery.

Authors:  Antonella Giannantoni; Savino M Di Stasi; Michael B Chancellor; Elisabetta Costantini; Massimo Porena
Journal:  Eur Urol       Date:  2006-08-30       Impact factor: 20.096

4.  Medium-term experience of sacral neuromodulation by tined lead implantation.

Authors:  Anco C Van Voskuilen; Dennis J A J Oerlemans; Ernest H J Weil; Ubi van den Hombergh; Philip E V A van Kerrebroeck
Journal:  BJU Int       Date:  2006-09-06       Impact factor: 5.588

5.  The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.

Authors:  Linda Cardozo; Andrew Thorpe; Juliet Warner; Manpreet Sidhu
Journal:  BJU Int       Date:  2010-02-03       Impact factor: 5.588

6.  Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.

Authors:  Debra E Irwin; Ian Milsom; Zoe Kopp; Paul Abrams; Walter Artibani; Sender Herschorn
Journal:  Eur Urol       Date:  2009-03-03       Impact factor: 20.096

7.  Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.

Authors:  Ling-Hong Tseng; Alex C Wang; Yao-Lung Chang; Yung-Kuei Soong; L Keith Lloyd; Yet-Jane Ko
Journal:  Neurourol Urodyn       Date:  2009       Impact factor: 2.696

8.  The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.

Authors:  Scott A Macdiarmid
Journal:  Rev Urol       Date:  2009

9.  Role of interstitial cells and gap junctions in the transmission of spontaneous Ca2+ signals in detrusor smooth muscles of the guinea-pig urinary bladder.

Authors:  Hikaru Hashitani; Yoshimasa Yanai; Hikaru Suzuki
Journal:  J Physiol       Date:  2004-07-02       Impact factor: 5.182

10.  Patient-reported reasons for discontinuing overactive bladder medication.

Authors:  Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

View more
  12 in total

1.  Role of the brain stem in tibial inhibition of the micturition reflex in cats.

Authors:  Matthew C Ferroni; Rick C Slater; Bing Shen; Zhiying Xiao; Jicheng Wang; Andy Lee; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  Am J Physiol Renal Physiol       Date:  2015-05-27

Review 2.  The placebo effect in overactive bladder syndrome.

Authors:  Altaf Mangera; Christopher R Chapple; Zoe S Kopp; Melanie Plested
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

Review 3.  Electrical nerve stimulation for overactive bladder in children.

Authors:  Ubirajara Barroso; Patrícia Lordêlo
Journal:  Nat Rev Urol       Date:  2011-06-07       Impact factor: 14.432

4.  Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells.

Authors:  L A Birder; A S Wolf-Johnston; Y Sun; T C Chai
Journal:  Acta Physiol (Oxf)       Date:  2012-07-12       Impact factor: 6.311

5.  Somatic modulation of spinal reflex bladder activity mediated by nociceptive bladder afferent nerve fibers in cats.

Authors:  Zhiying Xiao; Marc J Rogers; Bing Shen; Jicheng Wang; Zeyad Schwen; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-23

6.  Effects of kinin B(1) and B(2) receptor antagonists on overactive urinary bladder syndrome induced by spinal cord injury in rats.

Authors:  Stefânia Forner; Edinéia L Andrade; Alessandra C Martini; Allisson F Bento; Rodrigo Medeiros; Janice Koepp; João B Calixto
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 7.  Sex differences in the physiology and pharmacology of the lower urinary tract.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2013-02-08

8.  Comprehensive Review of Effective Application of Questionnaires for Clinical Research on Lower Urinary Tract Symptoms With Translation and Cultural Adaptation to the Korean Language.

Authors:  Jungyo Suh; Seung-June Oh; Sung Yong Cho
Journal:  Int Neurourol J       Date:  2020-12-31       Impact factor: 2.835

9.  Management of lower urinary tract dysfunction in patients with neurological disorders.

Authors:  Wen Ji Li; Seung-June Oh
Journal:  Korean J Urol       Date:  2012-09-19

10.  A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.

Authors:  Andrzej Wróbel; Aleksandra Szopa; Anna Serefko; Ewa Poleszak
Journal:  Molecules       Date:  2020-03-18       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.